AIRLINK 69.92 Increased By ▲ 4.72 (7.24%)
BOP 5.46 Decreased By ▼ -0.11 (-1.97%)
CNERGY 4.50 Decreased By ▼ -0.06 (-1.32%)
DFML 25.71 Increased By ▲ 1.19 (4.85%)
DGKC 69.85 Decreased By ▼ -0.11 (-0.16%)
FCCL 20.02 Decreased By ▼ -0.28 (-1.38%)
FFBL 30.69 Increased By ▲ 1.58 (5.43%)
FFL 9.75 Decreased By ▼ -0.08 (-0.81%)
GGL 10.12 Increased By ▲ 0.11 (1.1%)
HBL 114.90 Increased By ▲ 0.65 (0.57%)
HUBC 132.10 Increased By ▲ 3.00 (2.32%)
HUMNL 6.73 Increased By ▲ 0.02 (0.3%)
KEL 4.44 No Change ▼ 0.00 (0%)
KOSM 4.93 Increased By ▲ 0.04 (0.82%)
MLCF 36.45 Decreased By ▼ -0.55 (-1.49%)
OGDC 133.90 Increased By ▲ 1.60 (1.21%)
PAEL 22.50 Decreased By ▼ -0.04 (-0.18%)
PIAA 25.39 Decreased By ▼ -0.50 (-1.93%)
PIBTL 6.61 Increased By ▲ 0.01 (0.15%)
PPL 113.20 Increased By ▲ 0.35 (0.31%)
PRL 30.12 Increased By ▲ 0.71 (2.41%)
PTC 14.70 Decreased By ▼ -0.54 (-3.54%)
SEARL 57.55 Increased By ▲ 0.52 (0.91%)
SNGP 66.60 Increased By ▲ 0.15 (0.23%)
SSGC 10.99 Increased By ▲ 0.01 (0.09%)
TELE 8.77 Decreased By ▼ -0.03 (-0.34%)
TPLP 11.51 Decreased By ▼ -0.19 (-1.62%)
TRG 68.61 Decreased By ▼ -0.01 (-0.01%)
UNITY 23.47 Increased By ▲ 0.07 (0.3%)
WTL 1.34 Decreased By ▼ -0.04 (-2.9%)
BR100 7,399 Increased By 104.2 (1.43%)
BR30 24,136 Increased By 282 (1.18%)
KSE100 70,910 Increased By 619.8 (0.88%)
KSE30 23,377 Increased By 205.6 (0.89%)
World

COVID-19 'vaccine nationalism' could cost rich nations billions

  • “Governments are increasingly focusing on investments that can help their own economies to rebound,” said Hassan Damluji,
  • As per the Rand research report, the global cost associated with COVID-19 and its economic impact could be $3.4 trillion a year. For the EU it will be about 5.6 per cent in annual GDP, about $983 billion.
Published December 5, 2020

Rich nations stand to lose hundreds of billions of dollars in economic output over the next five years if poorer countries do not get equal access to COVID-19 vaccines, states a report as concerns grow about “vaccine nationalism”.

As the World Health Organisation (WHO) seeks to plug funding gaps in its ACT Accelerator programme for global COVID-19 treatments, researchers said their findings showed there was a financial - as well as a moral - case for ensuring equal access.

“Governments are increasingly focusing on investments that can help their own economies to rebound,” said Hassan Damluji, deputy director at the Bill & Melinda Gates Foundation, which commissioned the report by the Eurasia Group research firm.

“The ACT Accelerator is precisely one of those investments. It is both the right thing to do, and an investment that will pay dividends by bringing the global economy back from the brink, benefiting all nations.”

The ACT Accelerator (Access to COVID-19 Tools) is an international programme working to support the development of COVID-19 tests, treatments and vaccines and ensure they are available around the world.

As nations prepare to roll out mass COVID-19 vaccination programmes, with Britain becoming the first to approve a vaccine for use this week, there has been concern that “vaccine nationalism” could see poorer countries left behind.

The WHO says the programme needs $38 billion - of which about $28 billion is still outstanding, without which lower-income countries will not be able to get prompt access to COVID-19 drugs including vaccines.

Thursday’s report assessed the economic benefits of ensuring swift, equal global access to vaccines to 10 major economies - Canada, France, Germany, Japan, Qatar, South Korea, Sweden, United Arab Emirates, United Kingdom and the United States.

It found boosts to the global economy as a result meant they stood to gain at least $153 billion in 2020-21, and $466 billion by 2025, in an analysis based on IMF World Economic Outlook forecasts of varying vaccination scenarios.

Meanwhile, it is expected that Vaccine nationalism could lead to the unequal allocation of COVID-19 vaccines and cost the global economy up to $1.2 trillion a year in GDP terms.

Even if some countries manage to immunise their populations against the virus, as long as the virus is not under control in all regions of the world, there will continue to be a global economic cost associated with COVID-19.

Moreover, until there is a widely available vaccine for COVID-19, physical distancing measures will continue to affect key sectors of the global economy negatively, especially those that rely on close physical proximity between people.

As per the Rand research report, the global cost associated with COVID-19 and its economic impact could be $3.4 trillion a year. For the EU it will be about 5.6 per cent in annual GDP, about $983 billion. The loss incurred by the UK is about 4.3 per cent — an annual loss of about $145 billion. The US loses about 2.2 per cent in annual GDP, about $480 billion.

Based on previous estimates, it would cost $25 billion to supply lower income countries with vaccines. The US, the UK, the EU and other high-income countries combined could lose about $119 billion a year if the poorest countries are denied a supply, states the report.

If these high-income countries paid for the supply of vaccines, there could be a benefit-to-cost ratio of 4.8 to 1. For every $1 spent, high-income countries would get back about $4.8, it added.

WHO Director-General Tedros Adhanom Ghebreyesus hailed the report, and said contributing to the ACT Accelerator was “the smart thing for all countries – socially, economically and politically”.

Its findings are in line with an earlier study that found wealthy countries stood to lose $119 billion a year through uneven vaccine access, said Andrea Taylor, a researcher at the Duke Global Health Institute’s project tracking COVID-19 data.

“It is in the best interests of wealthy nations to invest in equity and it will cost all of us more if we don’t, both in terms of mortality and GDP,” she told the Thomson Reuters Foundation.

With input from Reuters

Comments

Comments are closed.